Global Macrolide Drugs Market
Global Macrolide Drugs Market

Macrolide Drugs Comprehensive Study by Type (Erythromycin, Clarithromycin, Azithromycin, Dirithromycin, Roxithromycin, Troleandomycin, Fidaxomicin, Telithromycin), Application (Mycoplasma Pneumoniae, Legionella sp., Bordetella Pertussis, Symptomatic Cat-scratch Disease, Bacillary Angiomatosis, Peliosishepatis, Cerebral Toxoplasmosis, Uncomplicated Skin Infections), End User (Hospital, Dermatology Clinic, Clinic, Ambulatory Centre, Research Laboratories) Players and Region - Global Market Outlook to 2026

Macrolide Drugs Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

Apr 2021 Edition 230 Pages 216 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Global Macrolide Drugs Market Overview:
Macrolides are antibacterial drugs with a large macrocyclic lactone ring that has been replaced with unusual sugars. Inhibitors of protein synthesis in dangerous and infectious gram-positive bacteria belong to this class of drugs. Increased prevalence of infectious diseases, an aging population, an increase in multidrug-resistant bacterial strains, and higher benefits over conventional antibiotics are all key growth factors for the industry.

Growth Drivers
  • Increasing Prevalence of Infectious Diseases
  • Growing Elderly Population
  • Increasing Number of Multidrug-resistant Bacterial Strains

Market Trends
  • Increased Research and Development Investments

Roadblocks
  • Side Effects of the Macrolide Drugs

Opportunities
  • Growth in the Healthcare Industry
  • Huge Investments by Major Players in the Market

Challenges
  • Stringent Government Rules and Regulations


Competitive Landscape:
The companies are exploring the market by adopting expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to gain a competitive advantage through combined collaborations.
Some of the key players profiled in the report are Eli Lilly & Co. (United States), Pfizer Inc. (United States), Sanofi (France), Merck & Co., Inc. (United States), Abbott Laboratories (United States) and Akorn, Inc. (United States). Analyst at AMA Research see United States Players to retain maximum share of Global Macrolide Drugs market by 2026. Considering Market by End User, the sub-segment i.e. Hospital will boost the Macrolide Drugs market.

In January 2021, Teva Pharmaceuticals USA, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd., has announced the availability of a generic version of NuvaRing (etonogestrel and Ethinyl estradiol vaginal ring), 0.120 mg/0.015 mg per day, in the U.S. Teva’s AB-rated and bioequivalent etonogestrel and ethinyl estradiol vaginal ring, is an estrogen/progestin combination hormonal contraceptive (CHC) indicated for use by women to prevent pregnancy.

Available Customization:
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be provided prior to purchase

Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Macrolide Drugs market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Macrolide Drugs market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Macrolide Drug Manufacturers, Research Organizations and Consulting Companies, Potential Technology Investors, Regulatory & Government Bodies, Downstream Vendors, End Users and Others.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.
Report Objectives / Segmentation Covered
By Type
  • Erythromycin
  • Clarithromycin
  • Azithromycin
  • Dirithromycin
  • Roxithromycin
  • Troleandomycin
  • Fidaxomicin
  • Telithromycin
By Application
  • Mycoplasma Pneumoniae
  • Legionella sp.
  • Bordetella Pertussis
  • Symptomatic Cat-scratch Disease
  • Bacillary Angiomatosis
  • Peliosishepatis
  • Cerebral Toxoplasmosis
  • Uncomplicated Skin Infections
By End User
  • Hospital
  • Dermatology Clinic
  • Clinic
  • Ambulatory Centre
  • Research Laboratories

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Prevalence of Infectious Diseases
      • 3.2.2. Growing Elderly Population
      • 3.2.3. Increasing Number of Multidrug-resistant Bacterial Strains
    • 3.3. Market Challenges
      • 3.3.1. Stringent Government Rules and Regulations
    • 3.4. Market Trends
      • 3.4.1. Increased Research and Development Investments
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Macrolide Drugs, by Type, Application, End User and Region (value and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Macrolide Drugs (Value)
      • 5.2.1. Global Macrolide Drugs by: Type (Value)
        • 5.2.1.1. Erythromycin
        • 5.2.1.2. Clarithromycin
        • 5.2.1.3. Azithromycin
        • 5.2.1.4. Dirithromycin
        • 5.2.1.5. Roxithromycin
        • 5.2.1.6. Troleandomycin
        • 5.2.1.7. Fidaxomicin
        • 5.2.1.8. Telithromycin
      • 5.2.2. Global Macrolide Drugs by: Application (Value)
        • 5.2.2.1. Mycoplasma Pneumoniae
        • 5.2.2.2. Legionella sp.
        • 5.2.2.3. Bordetella Pertussis
        • 5.2.2.4. Symptomatic Cat-scratch Disease
        • 5.2.2.5. Bacillary Angiomatosis
        • 5.2.2.6. Peliosishepatis
        • 5.2.2.7. Cerebral Toxoplasmosis
        • 5.2.2.8. Uncomplicated Skin Infections
      • 5.2.3. Global Macrolide Drugs by: End User (Value)
        • 5.2.3.1. Hospital
        • 5.2.3.2. Dermatology Clinic
        • 5.2.3.3. Clinic
        • 5.2.3.4. Ambulatory Centre
        • 5.2.3.5. Research Laboratories
      • 5.2.4. Global Macrolide Drugs Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Macrolide Drugs (Price)
      • 5.3.1. Global Macrolide Drugs by: Type (Price)
  • 6. Macrolide Drugs: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Eli Lilly & Co. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Pfizer Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Sanofi (France)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Merck & Co., Inc. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Abbott Laboratories (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Akorn, Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
  • 7. Global Macrolide Drugs Sale, by Type, Application, End User and Region (value and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Macrolide Drugs (Value)
      • 7.2.1. Global Macrolide Drugs by: Type (Value)
        • 7.2.1.1. Erythromycin
        • 7.2.1.2. Clarithromycin
        • 7.2.1.3. Azithromycin
        • 7.2.1.4. Dirithromycin
        • 7.2.1.5. Roxithromycin
        • 7.2.1.6. Troleandomycin
        • 7.2.1.7. Fidaxomicin
        • 7.2.1.8. Telithromycin
      • 7.2.2. Global Macrolide Drugs by: Application (Value)
        • 7.2.2.1. Mycoplasma Pneumoniae
        • 7.2.2.2. Legionella sp.
        • 7.2.2.3. Bordetella Pertussis
        • 7.2.2.4. Symptomatic Cat-scratch Disease
        • 7.2.2.5. Bacillary Angiomatosis
        • 7.2.2.6. Peliosishepatis
        • 7.2.2.7. Cerebral Toxoplasmosis
        • 7.2.2.8. Uncomplicated Skin Infections
      • 7.2.3. Global Macrolide Drugs by: End User (Value)
        • 7.2.3.1. Hospital
        • 7.2.3.2. Dermatology Clinic
        • 7.2.3.3. Clinic
        • 7.2.3.4. Ambulatory Centre
        • 7.2.3.5. Research Laboratories
      • 7.2.4. Global Macrolide Drugs Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Macrolide Drugs (Price)
      • 7.3.1. Global Macrolide Drugs by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Macrolide Drugs: by Type(USD Million)
  • Table 2. Macrolide Drugs Erythromycin , by Region USD Million (2015-2020)
  • Table 3. Macrolide Drugs Clarithromycin , by Region USD Million (2015-2020)
  • Table 4. Macrolide Drugs Azithromycin , by Region USD Million (2015-2020)
  • Table 5. Macrolide Drugs Dirithromycin , by Region USD Million (2015-2020)
  • Table 6. Macrolide Drugs Roxithromycin , by Region USD Million (2015-2020)
  • Table 7. Macrolide Drugs Troleandomycin , by Region USD Million (2015-2020)
  • Table 8. Macrolide Drugs Fidaxomicin , by Region USD Million (2015-2020)
  • Table 9. Macrolide Drugs Telithromycin , by Region USD Million (2015-2020)
  • Table 10. Macrolide Drugs: by Application(USD Million)
  • Table 11. Macrolide Drugs Mycoplasma Pneumoniae , by Region USD Million (2015-2020)
  • Table 12. Macrolide Drugs Legionella sp. , by Region USD Million (2015-2020)
  • Table 13. Macrolide Drugs Bordetella Pertussis , by Region USD Million (2015-2020)
  • Table 14. Macrolide Drugs Symptomatic Cat-scratch Disease , by Region USD Million (2015-2020)
  • Table 15. Macrolide Drugs Bacillary Angiomatosis , by Region USD Million (2015-2020)
  • Table 16. Macrolide Drugs Peliosishepatis , by Region USD Million (2015-2020)
  • Table 17. Macrolide Drugs Cerebral Toxoplasmosis , by Region USD Million (2015-2020)
  • Table 18. Macrolide Drugs Uncomplicated Skin Infections , by Region USD Million (2015-2020)
  • Table 19. Macrolide Drugs: by End User(USD Million)
  • Table 20. Macrolide Drugs Hospital , by Region USD Million (2015-2020)
  • Table 21. Macrolide Drugs Dermatology Clinic , by Region USD Million (2015-2020)
  • Table 22. Macrolide Drugs Clinic , by Region USD Million (2015-2020)
  • Table 23. Macrolide Drugs Ambulatory Centre , by Region USD Million (2015-2020)
  • Table 24. Macrolide Drugs Research Laboratories , by Region USD Million (2015-2020)
  • Table 25. South America Macrolide Drugs, by Country USD Million (2015-2020)
  • Table 26. South America Macrolide Drugs, by Type USD Million (2015-2020)
  • Table 27. South America Macrolide Drugs, by Application USD Million (2015-2020)
  • Table 28. South America Macrolide Drugs, by End User USD Million (2015-2020)
  • Table 29. Brazil Macrolide Drugs, by Type USD Million (2015-2020)
  • Table 30. Brazil Macrolide Drugs, by Application USD Million (2015-2020)
  • Table 31. Brazil Macrolide Drugs, by End User USD Million (2015-2020)
  • Table 32. Argentina Macrolide Drugs, by Type USD Million (2015-2020)
  • Table 33. Argentina Macrolide Drugs, by Application USD Million (2015-2020)
  • Table 34. Argentina Macrolide Drugs, by End User USD Million (2015-2020)
  • Table 35. Rest of South America Macrolide Drugs, by Type USD Million (2015-2020)
  • Table 36. Rest of South America Macrolide Drugs, by Application USD Million (2015-2020)
  • Table 37. Rest of South America Macrolide Drugs, by End User USD Million (2015-2020)
  • Table 38. Asia Pacific Macrolide Drugs, by Country USD Million (2015-2020)
  • Table 39. Asia Pacific Macrolide Drugs, by Type USD Million (2015-2020)
  • Table 40. Asia Pacific Macrolide Drugs, by Application USD Million (2015-2020)
  • Table 41. Asia Pacific Macrolide Drugs, by End User USD Million (2015-2020)
  • Table 42. China Macrolide Drugs, by Type USD Million (2015-2020)
  • Table 43. China Macrolide Drugs, by Application USD Million (2015-2020)
  • Table 44. China Macrolide Drugs, by End User USD Million (2015-2020)
  • Table 45. Japan Macrolide Drugs, by Type USD Million (2015-2020)
  • Table 46. Japan Macrolide Drugs, by Application USD Million (2015-2020)
  • Table 47. Japan Macrolide Drugs, by End User USD Million (2015-2020)
  • Table 48. India Macrolide Drugs, by Type USD Million (2015-2020)
  • Table 49. India Macrolide Drugs, by Application USD Million (2015-2020)
  • Table 50. India Macrolide Drugs, by End User USD Million (2015-2020)
  • Table 51. South Korea Macrolide Drugs, by Type USD Million (2015-2020)
  • Table 52. South Korea Macrolide Drugs, by Application USD Million (2015-2020)
  • Table 53. South Korea Macrolide Drugs, by End User USD Million (2015-2020)
  • Table 54. Taiwan Macrolide Drugs, by Type USD Million (2015-2020)
  • Table 55. Taiwan Macrolide Drugs, by Application USD Million (2015-2020)
  • Table 56. Taiwan Macrolide Drugs, by End User USD Million (2015-2020)
  • Table 57. Australia Macrolide Drugs, by Type USD Million (2015-2020)
  • Table 58. Australia Macrolide Drugs, by Application USD Million (2015-2020)
  • Table 59. Australia Macrolide Drugs, by End User USD Million (2015-2020)
  • Table 60. Rest of Asia-Pacific Macrolide Drugs, by Type USD Million (2015-2020)
  • Table 61. Rest of Asia-Pacific Macrolide Drugs, by Application USD Million (2015-2020)
  • Table 62. Rest of Asia-Pacific Macrolide Drugs, by End User USD Million (2015-2020)
  • Table 63. Europe Macrolide Drugs, by Country USD Million (2015-2020)
  • Table 64. Europe Macrolide Drugs, by Type USD Million (2015-2020)
  • Table 65. Europe Macrolide Drugs, by Application USD Million (2015-2020)
  • Table 66. Europe Macrolide Drugs, by End User USD Million (2015-2020)
  • Table 67. Germany Macrolide Drugs, by Type USD Million (2015-2020)
  • Table 68. Germany Macrolide Drugs, by Application USD Million (2015-2020)
  • Table 69. Germany Macrolide Drugs, by End User USD Million (2015-2020)
  • Table 70. France Macrolide Drugs, by Type USD Million (2015-2020)
  • Table 71. France Macrolide Drugs, by Application USD Million (2015-2020)
  • Table 72. France Macrolide Drugs, by End User USD Million (2015-2020)
  • Table 73. Italy Macrolide Drugs, by Type USD Million (2015-2020)
  • Table 74. Italy Macrolide Drugs, by Application USD Million (2015-2020)
  • Table 75. Italy Macrolide Drugs, by End User USD Million (2015-2020)
  • Table 76. United Kingdom Macrolide Drugs, by Type USD Million (2015-2020)
  • Table 77. United Kingdom Macrolide Drugs, by Application USD Million (2015-2020)
  • Table 78. United Kingdom Macrolide Drugs, by End User USD Million (2015-2020)
  • Table 79. Netherlands Macrolide Drugs, by Type USD Million (2015-2020)
  • Table 80. Netherlands Macrolide Drugs, by Application USD Million (2015-2020)
  • Table 81. Netherlands Macrolide Drugs, by End User USD Million (2015-2020)
  • Table 82. Rest of Europe Macrolide Drugs, by Type USD Million (2015-2020)
  • Table 83. Rest of Europe Macrolide Drugs, by Application USD Million (2015-2020)
  • Table 84. Rest of Europe Macrolide Drugs, by End User USD Million (2015-2020)
  • Table 85. MEA Macrolide Drugs, by Country USD Million (2015-2020)
  • Table 86. MEA Macrolide Drugs, by Type USD Million (2015-2020)
  • Table 87. MEA Macrolide Drugs, by Application USD Million (2015-2020)
  • Table 88. MEA Macrolide Drugs, by End User USD Million (2015-2020)
  • Table 89. Middle East Macrolide Drugs, by Type USD Million (2015-2020)
  • Table 90. Middle East Macrolide Drugs, by Application USD Million (2015-2020)
  • Table 91. Middle East Macrolide Drugs, by End User USD Million (2015-2020)
  • Table 92. Africa Macrolide Drugs, by Type USD Million (2015-2020)
  • Table 93. Africa Macrolide Drugs, by Application USD Million (2015-2020)
  • Table 94. Africa Macrolide Drugs, by End User USD Million (2015-2020)
  • Table 95. North America Macrolide Drugs, by Country USD Million (2015-2020)
  • Table 96. North America Macrolide Drugs, by Type USD Million (2015-2020)
  • Table 97. North America Macrolide Drugs, by Application USD Million (2015-2020)
  • Table 98. North America Macrolide Drugs, by End User USD Million (2015-2020)
  • Table 99. United States Macrolide Drugs, by Type USD Million (2015-2020)
  • Table 100. United States Macrolide Drugs, by Application USD Million (2015-2020)
  • Table 101. United States Macrolide Drugs, by End User USD Million (2015-2020)
  • Table 102. Canada Macrolide Drugs, by Type USD Million (2015-2020)
  • Table 103. Canada Macrolide Drugs, by Application USD Million (2015-2020)
  • Table 104. Canada Macrolide Drugs, by End User USD Million (2015-2020)
  • Table 105. Mexico Macrolide Drugs, by Type USD Million (2015-2020)
  • Table 106. Mexico Macrolide Drugs, by Application USD Million (2015-2020)
  • Table 107. Mexico Macrolide Drugs, by End User USD Million (2015-2020)
  • Table 108. Macrolide Drugs: by Type(USD/Units)
  • Table 109. Company Basic Information, Sales Area and Its Competitors
  • Table 110. Company Basic Information, Sales Area and Its Competitors
  • Table 111. Company Basic Information, Sales Area and Its Competitors
  • Table 112. Company Basic Information, Sales Area and Its Competitors
  • Table 113. Company Basic Information, Sales Area and Its Competitors
  • Table 114. Company Basic Information, Sales Area and Its Competitors
  • Table 115. Macrolide Drugs: by Type(USD Million)
  • Table 116. Macrolide Drugs Erythromycin , by Region USD Million (2021-2026)
  • Table 117. Macrolide Drugs Clarithromycin , by Region USD Million (2021-2026)
  • Table 118. Macrolide Drugs Azithromycin , by Region USD Million (2021-2026)
  • Table 119. Macrolide Drugs Dirithromycin , by Region USD Million (2021-2026)
  • Table 120. Macrolide Drugs Roxithromycin , by Region USD Million (2021-2026)
  • Table 121. Macrolide Drugs Troleandomycin , by Region USD Million (2021-2026)
  • Table 122. Macrolide Drugs Fidaxomicin , by Region USD Million (2021-2026)
  • Table 123. Macrolide Drugs Telithromycin , by Region USD Million (2021-2026)
  • Table 124. Macrolide Drugs: by Application(USD Million)
  • Table 125. Macrolide Drugs Mycoplasma Pneumoniae , by Region USD Million (2021-2026)
  • Table 126. Macrolide Drugs Legionella sp. , by Region USD Million (2021-2026)
  • Table 127. Macrolide Drugs Bordetella Pertussis , by Region USD Million (2021-2026)
  • Table 128. Macrolide Drugs Symptomatic Cat-scratch Disease , by Region USD Million (2021-2026)
  • Table 129. Macrolide Drugs Bacillary Angiomatosis , by Region USD Million (2021-2026)
  • Table 130. Macrolide Drugs Peliosishepatis , by Region USD Million (2021-2026)
  • Table 131. Macrolide Drugs Cerebral Toxoplasmosis , by Region USD Million (2021-2026)
  • Table 132. Macrolide Drugs Uncomplicated Skin Infections , by Region USD Million (2021-2026)
  • Table 133. Macrolide Drugs: by End User(USD Million)
  • Table 134. Macrolide Drugs Hospital , by Region USD Million (2021-2026)
  • Table 135. Macrolide Drugs Dermatology Clinic , by Region USD Million (2021-2026)
  • Table 136. Macrolide Drugs Clinic , by Region USD Million (2021-2026)
  • Table 137. Macrolide Drugs Ambulatory Centre , by Region USD Million (2021-2026)
  • Table 138. Macrolide Drugs Research Laboratories , by Region USD Million (2021-2026)
  • Table 139. South America Macrolide Drugs, by Country USD Million (2021-2026)
  • Table 140. South America Macrolide Drugs, by Type USD Million (2021-2026)
  • Table 141. South America Macrolide Drugs, by Application USD Million (2021-2026)
  • Table 142. South America Macrolide Drugs, by End User USD Million (2021-2026)
  • Table 143. Brazil Macrolide Drugs, by Type USD Million (2021-2026)
  • Table 144. Brazil Macrolide Drugs, by Application USD Million (2021-2026)
  • Table 145. Brazil Macrolide Drugs, by End User USD Million (2021-2026)
  • Table 146. Argentina Macrolide Drugs, by Type USD Million (2021-2026)
  • Table 147. Argentina Macrolide Drugs, by Application USD Million (2021-2026)
  • Table 148. Argentina Macrolide Drugs, by End User USD Million (2021-2026)
  • Table 149. Rest of South America Macrolide Drugs, by Type USD Million (2021-2026)
  • Table 150. Rest of South America Macrolide Drugs, by Application USD Million (2021-2026)
  • Table 151. Rest of South America Macrolide Drugs, by End User USD Million (2021-2026)
  • Table 152. Asia Pacific Macrolide Drugs, by Country USD Million (2021-2026)
  • Table 153. Asia Pacific Macrolide Drugs, by Type USD Million (2021-2026)
  • Table 154. Asia Pacific Macrolide Drugs, by Application USD Million (2021-2026)
  • Table 155. Asia Pacific Macrolide Drugs, by End User USD Million (2021-2026)
  • Table 156. China Macrolide Drugs, by Type USD Million (2021-2026)
  • Table 157. China Macrolide Drugs, by Application USD Million (2021-2026)
  • Table 158. China Macrolide Drugs, by End User USD Million (2021-2026)
  • Table 159. Japan Macrolide Drugs, by Type USD Million (2021-2026)
  • Table 160. Japan Macrolide Drugs, by Application USD Million (2021-2026)
  • Table 161. Japan Macrolide Drugs, by End User USD Million (2021-2026)
  • Table 162. India Macrolide Drugs, by Type USD Million (2021-2026)
  • Table 163. India Macrolide Drugs, by Application USD Million (2021-2026)
  • Table 164. India Macrolide Drugs, by End User USD Million (2021-2026)
  • Table 165. South Korea Macrolide Drugs, by Type USD Million (2021-2026)
  • Table 166. South Korea Macrolide Drugs, by Application USD Million (2021-2026)
  • Table 167. South Korea Macrolide Drugs, by End User USD Million (2021-2026)
  • Table 168. Taiwan Macrolide Drugs, by Type USD Million (2021-2026)
  • Table 169. Taiwan Macrolide Drugs, by Application USD Million (2021-2026)
  • Table 170. Taiwan Macrolide Drugs, by End User USD Million (2021-2026)
  • Table 171. Australia Macrolide Drugs, by Type USD Million (2021-2026)
  • Table 172. Australia Macrolide Drugs, by Application USD Million (2021-2026)
  • Table 173. Australia Macrolide Drugs, by End User USD Million (2021-2026)
  • Table 174. Rest of Asia-Pacific Macrolide Drugs, by Type USD Million (2021-2026)
  • Table 175. Rest of Asia-Pacific Macrolide Drugs, by Application USD Million (2021-2026)
  • Table 176. Rest of Asia-Pacific Macrolide Drugs, by End User USD Million (2021-2026)
  • Table 177. Europe Macrolide Drugs, by Country USD Million (2021-2026)
  • Table 178. Europe Macrolide Drugs, by Type USD Million (2021-2026)
  • Table 179. Europe Macrolide Drugs, by Application USD Million (2021-2026)
  • Table 180. Europe Macrolide Drugs, by End User USD Million (2021-2026)
  • Table 181. Germany Macrolide Drugs, by Type USD Million (2021-2026)
  • Table 182. Germany Macrolide Drugs, by Application USD Million (2021-2026)
  • Table 183. Germany Macrolide Drugs, by End User USD Million (2021-2026)
  • Table 184. France Macrolide Drugs, by Type USD Million (2021-2026)
  • Table 185. France Macrolide Drugs, by Application USD Million (2021-2026)
  • Table 186. France Macrolide Drugs, by End User USD Million (2021-2026)
  • Table 187. Italy Macrolide Drugs, by Type USD Million (2021-2026)
  • Table 188. Italy Macrolide Drugs, by Application USD Million (2021-2026)
  • Table 189. Italy Macrolide Drugs, by End User USD Million (2021-2026)
  • Table 190. United Kingdom Macrolide Drugs, by Type USD Million (2021-2026)
  • Table 191. United Kingdom Macrolide Drugs, by Application USD Million (2021-2026)
  • Table 192. United Kingdom Macrolide Drugs, by End User USD Million (2021-2026)
  • Table 193. Netherlands Macrolide Drugs, by Type USD Million (2021-2026)
  • Table 194. Netherlands Macrolide Drugs, by Application USD Million (2021-2026)
  • Table 195. Netherlands Macrolide Drugs, by End User USD Million (2021-2026)
  • Table 196. Rest of Europe Macrolide Drugs, by Type USD Million (2021-2026)
  • Table 197. Rest of Europe Macrolide Drugs, by Application USD Million (2021-2026)
  • Table 198. Rest of Europe Macrolide Drugs, by End User USD Million (2021-2026)
  • Table 199. MEA Macrolide Drugs, by Country USD Million (2021-2026)
  • Table 200. MEA Macrolide Drugs, by Type USD Million (2021-2026)
  • Table 201. MEA Macrolide Drugs, by Application USD Million (2021-2026)
  • Table 202. MEA Macrolide Drugs, by End User USD Million (2021-2026)
  • Table 203. Middle East Macrolide Drugs, by Type USD Million (2021-2026)
  • Table 204. Middle East Macrolide Drugs, by Application USD Million (2021-2026)
  • Table 205. Middle East Macrolide Drugs, by End User USD Million (2021-2026)
  • Table 206. Africa Macrolide Drugs, by Type USD Million (2021-2026)
  • Table 207. Africa Macrolide Drugs, by Application USD Million (2021-2026)
  • Table 208. Africa Macrolide Drugs, by End User USD Million (2021-2026)
  • Table 209. North America Macrolide Drugs, by Country USD Million (2021-2026)
  • Table 210. North America Macrolide Drugs, by Type USD Million (2021-2026)
  • Table 211. North America Macrolide Drugs, by Application USD Million (2021-2026)
  • Table 212. North America Macrolide Drugs, by End User USD Million (2021-2026)
  • Table 213. United States Macrolide Drugs, by Type USD Million (2021-2026)
  • Table 214. United States Macrolide Drugs, by Application USD Million (2021-2026)
  • Table 215. United States Macrolide Drugs, by End User USD Million (2021-2026)
  • Table 216. Canada Macrolide Drugs, by Type USD Million (2021-2026)
  • Table 217. Canada Macrolide Drugs, by Application USD Million (2021-2026)
  • Table 218. Canada Macrolide Drugs, by End User USD Million (2021-2026)
  • Table 219. Mexico Macrolide Drugs, by Type USD Million (2021-2026)
  • Table 220. Mexico Macrolide Drugs, by Application USD Million (2021-2026)
  • Table 221. Mexico Macrolide Drugs, by End User USD Million (2021-2026)
  • Table 222. Macrolide Drugs: by Type(USD/Units)
  • Table 223. Research Programs/Design for This Report
  • Table 224. Key Data Information from Secondary Sources
  • Table 225. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Macrolide Drugs: by Type USD Million (2015-2020)
  • Figure 5. Global Macrolide Drugs: by Application USD Million (2015-2020)
  • Figure 6. Global Macrolide Drugs: by End User USD Million (2015-2020)
  • Figure 7. South America Macrolide Drugs Share (%), by Country
  • Figure 8. Asia Pacific Macrolide Drugs Share (%), by Country
  • Figure 9. Europe Macrolide Drugs Share (%), by Country
  • Figure 10. MEA Macrolide Drugs Share (%), by Country
  • Figure 11. North America Macrolide Drugs Share (%), by Country
  • Figure 12. Global Macrolide Drugs: by Type USD/Units (2015-2020)
  • Figure 13. Global Macrolide Drugs share by Players 2020 (%)
  • Figure 14. Global Macrolide Drugs share by Players (Top 3) 2020(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Eli Lilly & Co. (United States) Revenue, Net Income and Gross profit
  • Figure 17. Eli Lilly & Co. (United States) Revenue: by Geography 2020
  • Figure 18. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 19. Pfizer Inc. (United States) Revenue: by Geography 2020
  • Figure 20. Sanofi (France) Revenue, Net Income and Gross profit
  • Figure 21. Sanofi (France) Revenue: by Geography 2020
  • Figure 22. Merck & Co., Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 23. Merck & Co., Inc. (United States) Revenue: by Geography 2020
  • Figure 24. Abbott Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 25. Abbott Laboratories (United States) Revenue: by Geography 2020
  • Figure 26. Akorn, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 27. Akorn, Inc. (United States) Revenue: by Geography 2020
  • Figure 28. Global Macrolide Drugs: by Type USD Million (2021-2026)
  • Figure 29. Global Macrolide Drugs: by Application USD Million (2021-2026)
  • Figure 30. Global Macrolide Drugs: by End User USD Million (2021-2026)
  • Figure 31. South America Macrolide Drugs Share (%), by Country
  • Figure 32. Asia Pacific Macrolide Drugs Share (%), by Country
  • Figure 33. Europe Macrolide Drugs Share (%), by Country
  • Figure 34. MEA Macrolide Drugs Share (%), by Country
  • Figure 35. North America Macrolide Drugs Share (%), by Country
  • Figure 36. Global Macrolide Drugs: by Type USD/Units (2021-2026)
Some of the key companies/manufacturers profiled in the report
  • Eli Lilly & Co. (United States)
  • Pfizer Inc. (United States)
  • Sanofi (France)
  • Merck & Co., Inc. (United States)
  • Abbott Laboratories (United States)
  • Akorn, Inc. (United States)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation